Lead Product(s) : Remestemcel-L
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : $90.0 million
Deal Type : Financing
Details : A significant portion of the net proceeds will be used to scale-up manufacturing of remestemcel-L for the treatment of critically ill patients suffering with diseases caused by cytokine release syndromes associated with high mortality, particularly COVID...
Product Name : Ryoncil
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 13, 2020
Lead Product(s) : Remestemcel-L
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : $90.0 million
Deal Type : Financing